factually
Index/Topics/Bremelanotide Approval

Bremelanotide Approval

Bremelanotide was approved by the FDA for the treatment of female hypoactive sexual desire based on phase 3, randomized, double-blind, placebo-controlled trials.

Fact-Checks

2 results
Jan 27, 2026
Most Viewed

What evidence supports off‑label testosterone or PT‑141 for female low libido and what are the regulatory positions?

Two pharmacologic approaches are commonly discussed for : off‑label therapy and (PT‑141). Clinical trial evidence supports bremelanotide for hypoactive sexual desire disorder (HSDD) in premenopausal w...

Jan 29, 2026
Most Viewed

Are there head‑to‑head trials comparing bremelanotide, flibanserin, and testosterone for female low libido?

There are no published randomized, head‑to‑head clinical trials directly comparing , , and for ; the available evidence comes from separate placebo‑controlled trials, systematic reviews, and critiques...